Format

Send to

Choose Destination
Indian J Dermatol Venereol Leprol. 2004 Sep-Oct;70(5):288-91.

Efficacy of desonide 0.05% cream and lotion in steroid-responsive dermatoses in Indian patients: a post-marketing surveillance study.

Author information

1
Galderma India Pvt. Ltd, Mumbai, India.

Abstract

BACKGROUND:

Desonide, a non-halogenated, low-potency topical steroid, is indicated in the treatment of steroid-responsive dermatoses.

AIMS:

A post-marketing surveillance study was conducted to evaluate the efficacy and safety of Desowen (Desonide 0.05%) cream and lotion in Indian patients for the treatment of steroid-responsive dermatoses of mild to moderate severity.

METHODS:

A 3-week, multicenter, open-label, non-comparative Phase IV trial involving 1789 patients from 229 centers across India was conducted between January and August 2003.

RESULTS:

Of the 1789 patients, 1483 patients completed the treatment as per protocol. At the end of the therapy, 98.5% of the patients showed an improvement in their dermatitis from baseline. More than half of the patients showed a greater than 75% improvement in their signs and symptoms. No adverse effects were noted in any of the patients. Both the lotion and cream were found to be equally effective.

CONCLUSIONS:

Desonide 0.05% is a safe and effective low-potency corticosteroid for the treatment of mild to moderate dermatoses in Indian patients. No clinically apparent side-effects were observed in infants less than 1 year of age.

PMID:
17642640
Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center